Irreversible protein kinase inhibitors: balancing the benefits and risks.
about
A safe lithium mimetic for bipolar disorderRecent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET ImagingExploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?Developing irreversible inhibitors of the protein kinase cysteinomeExploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics SimulationCovalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition ReactionsPseudokinases: update on their functions and evaluation as new drug targets.A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.Phenylalanine-Based Inactivator of AKT Kinase: Design, Synthesis, and Biological Evaluation.Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors.Protein tyrosine phosphatases as potential therapeutic targets.Polypharmacology: drug discovery for the future.Covalent-Allosteric Kinase Inhibitors.Prolonged and tunable residence time using reversible covalent kinase inhibitors.Identification and Characterization of an Irreversible Inhibitor of CDK2.Designing Irreversible Inhibitors--Worth the Effort?Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) InhibitorsAn NMR-Guided Screening Method for Selective Fragment Docking and Synthesis of a Warhead Inhibitor.Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine.Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells.Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.Epidermal growth factor receptor inhibitors: a patent review (2010 - present).Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.Recent advances in irreversible kinase inhibitors.Targeting protein kinases with selective and semipromiscuous covalent inhibitors.Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.New drug design with covalent modifiers.Design, Synthesis and Anti-Proliferative Activities of 2,6-Substituted Thieno[3,2-d]pyrimidine Derivatives Containing Electrophilic Warheads.Heat shock protein 70 inhibitors. 2. 2,5'-thiodipyrimidines, 5-(phenylthio)pyrimidines, 2-(pyridin-3-ylthio)pyrimidines, and 3-(phenylthio)pyridines as reversible binders to an allosteric site on heat shock protein 70.Antiproliferative activities of halogenated pyrrolo[3,2-d]pyrimidinesTargeted Covalent Inhibitors for Drug Design.cBinderDB: a covalent binding agent database.Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors.Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A.Non-kinase targets of protein kinase inhibitors.Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound-Kinase Activities: A Way toward Selective Promiscuity by Design?Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography.Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.A chemoproteomic method for identifying cellular targets of covalent kinase inhibitors.
P2860
Q24600175-C1304363-D6E7-412B-8531-8C1353607FB3Q26774478-265AA922-517D-4119-A200-F4822733DDCFQ27001584-627B0608-A504-4513-98E7-3EBA38079DB1Q27027983-C9BEE4CA-7FE3-4E2D-9FBB-9EF23E0452ADQ28552585-92B8D441-8DBE-4461-ACE4-5F286768163EQ29248430-F2F69CF7-BEC7-4738-BF70-A6FB634ED2E7Q30397636-2FFFADA2-822A-4E5B-9ADF-553D264BA0B2Q33605906-3EC58455-6DE3-4B38-8205-57F03E596AAAQ33636467-BA7F7E1F-496B-423A-A2BB-CF14DCB5D4E4Q33859476-9C4680E0-82B2-460E-BDFB-E572BA737EFEQ34067085-5AA23AFF-3619-40ED-A921-BA5988B2BA28Q34295063-A04C71C9-1BCB-40F7-9BD5-8D87F9A43E44Q34319906-7234AC32-B7EE-47DD-9456-698F55432FC9Q35674207-C526E58A-84F8-4C76-A274-074A2E63EEB2Q35756228-8CF72144-C873-4559-8C78-0FF308B372D2Q35759866-FF2B8351-7206-4BFD-BE20-B059AFE3CF76Q35848315-18C8FB9B-A078-4012-B758-6EB074DE201BQ36059792-C48EC8CC-D99E-46EC-A98F-63809B69E097Q36083038-5C706EAD-307E-408A-AC6B-5D96BBC40C55Q36405755-A2422BC7-59F7-4FE6-AFA3-5007FBE85043Q36946655-7702EDB5-0521-4D1E-95B4-454FE68678D7Q37571930-2F38DA4E-04BA-47FF-9635-F1274C1B8909Q38175432-57E12C30-0605-4685-B087-E0A96AB61618Q38253835-CA9F920F-A0E6-429A-86BC-77F05853B945Q38257746-9237F2A7-54B8-4C7A-AD43-B5B1B41D6110Q38268506-FE260A1D-59F1-427A-BABD-AD627411B6CBQ38676572-7E408A8E-A9E9-41E7-AF4A-C06B5573466AQ38693434-FA57E272-8A34-4CAA-9544-719B8AF61C4DQ38703752-793AFE12-DDE5-4CFA-8C3A-40317FEFD305Q38705732-2060A176-7F5E-4FC0-8695-F04E12B6CC5DQ38858891-9A03BDEA-70EE-4D9A-96DA-E199B5956AE9Q38931379-0CBCC426-A7A0-4770-80A6-E2FB5DD8CA24Q39067557-1337B508-4D9C-45B6-98FD-88A52DAD98B1Q39079553-4CE6959D-709A-4C9E-AA23-91C387B82BE3Q39120175-085EC8B0-5264-4F3C-A637-C77C4E7C93A8Q39171961-D22AD18F-E5F2-4DD5-8651-901E5232AC29Q39534317-9A1AF42A-201F-4BC7-9E22-800D04AF4882Q40076123-DEB4FC89-3764-4458-9C5F-9EC6C3728897Q42023703-263FA32B-7A84-4780-8B96-CE41AB76F6EDQ42126143-CC7BF2FE-EDDE-497D-A573-9A99BF360EA3
P2860
Irreversible protein kinase inhibitors: balancing the benefits and risks.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Irreversible protein kinase inhibitors: balancing the benefits and risks.
@en
type
label
Irreversible protein kinase inhibitors: balancing the benefits and risks.
@en
prefLabel
Irreversible protein kinase inhibitors: balancing the benefits and risks.
@en
P356
P1476
Irreversible protein kinase inhibitors: balancing the benefits and risks.
@en
P2093
Allard Kaptein
Tjeerd Barf
P304
P356
10.1021/JM3003203
P407
P577
2012-06-08T00:00:00Z